{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:49:44Z","timestamp":1780616984691,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clindermatol.2025.09.014","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:30:31Z","timestamp":1760027431000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Skin cancer and human immunodeficiency virus"],"prefix":"10.1016","volume":"44","author":[{"given":"Cory","family":"Kosche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin TW","family":"Chio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Arron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2025.09.014_bib0001","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","article-title":"Incidence Estimate of nonmelanoma skin cancer in the United States, 2006","volume":"146","author":"Rogers","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"Cesarman","year":"2019","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0003","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(21)00137-6","article-title":"The effect of non-AIDS-defining cancers on people living with HIV","volume":"22","author":"Chiao","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0004","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Collaboration","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0005","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/0956462415586316","article-title":"The risk of non-melanoma skin cancer in HIV-infected patients: new data and meta-analysis","volume":"27","author":"Zhao","year":"2016","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0006","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djs529","article-title":"HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer","volume":"105","author":"Silverberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0007","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jaad.2020.02.013","article-title":"Skin cancer and skin cancer risk behaviors among sexual and gender minority populations: a systematic review","volume":"83","author":"Singer","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jamadermatol.2018.0003","article-title":"Indoor tanning, sunless tanning, and sun-protection behaviors among sexual minority men","volume":"154","author":"Gao","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0009","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1346-8138.2000.tb02185.x","article-title":"Photosensitivity in HIV-Infected Individuals","volume":"27","author":"Vin-Christian","year":"2000","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jac\/dkn292","article-title":"Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection","volume":"62","author":"Borr\u00e1s-Blasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0011","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1001\/jamadermatol.2017.1716","article-title":"Association of multiple primary skin cancers with human immunodeficiency virus infection, CD4 count, and viral load","volume":"153","author":"Asgari","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0012","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archderm.138.6.758","article-title":"Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus","volume":"138","author":"Nguyen","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0013","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/2013.jamadermatol.245","article-title":"Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus","volume":"149","author":"Hausauer","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0014","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archderm.1992.01680150053003","article-title":"Nonmelanoma skin cancers and infection with the human immunodeficiency virus","volume":"12","author":"Lobo","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0015","first-page":"591","article-title":"Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030","volume":"64","author":"Guy","year":"2015","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/858425","article-title":"Worldwide increasing incidences of cutaneous malignant melanoma","volume":"2011","author":"Godar","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/QAI.0000000000001719","article-title":"Brief report: cutaneous melanoma risk among people with HIV in the United States and Canada","volume":"78","author":"Yanik","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095096","article-title":"Risk of melanoma in people with HIV\/AIDS in the pre-and post-HAART eras: a systematic review and meta-analysis of cohort studies","volume":"9","author":"Olsen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0019","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1055-9965.EPI-11-0777","article-title":"HIV infection, immunodeficiency, viral replication, and the risk of cancer","volume":"20","author":"Silverberg","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-1440-3-10","article-title":"Systematic review of melanoma incidence and prognosis in solid organ transplant recipients","volume":"3","author":"Dahlke","year":"2014","journal-title":"Transplant Res"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0021","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamadermatol.2016.4920","article-title":"Incidence of and risk factors for skin cancer in organ transplant recipients in the United States","volume":"153","author":"Garrett","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0022","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archderm.138.6.765","article-title":"Altered clinical course of malignant melanoma in HIV-positive patients","volume":"138","author":"Rodrigues","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0023","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/jid.2012.388","article-title":"Systemic immune suppression predicts diminished merkel cell carcinoma\u2013specific survival independent of stage","volume":"133","author":"Paulson","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0024","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","article-title":"Merkel cell carcinoma and HIV infection","volume":"359","author":"Engels","year":"2002","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.clindermatol.2025.09.014_bib0025","doi-asserted-by":"crossref","first-page":"O10","DOI":"10.1186\/1750-9378-4-S2-O10","article-title":"Epidemiology of non-keratinocytic skin cancers among persons with AIDS in the United States","volume":"4","author":"Lanoy","year":"2009","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/QAD.0b013e328340a19c","article-title":"Merkel cell carcinoma associated with HIV: review of 14 patients","volume":"25","author":"Izikson","year":"2011","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0027","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/QAD.0000000000000682","article-title":"Epidemiology of Kaposi\u2019s sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy","volume":"29","author":"Labo","year":"2015","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jama.2016.8465","article-title":"Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/mmt-2016-0022","article-title":"Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy","volume":"4","author":"Johnson","year":"2017","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0032","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bjps.2010.07.006","article-title":"Revised UK guidelines for the management of cutaneous melanoma 2010","volume":"63","author":"Marsden","year":"2010","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0033","unstructured":"Mann G, Cust AE, Damian DL, Fishburn P, Kelly JW, Mar V, Soyer HP; Cancer Council Australia Melanoma Guidelines Working Party. Guidelines: Who is at high risk of new primary melanoma and how should risk be managed? In: Clinical practice guidelines for the diagnosis and management of melanoma. Accessed May 23, 2022. https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma."},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0034","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canep.2010.03.006","article-title":"A nationwide population-based skin cancer screening in Germany: Proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009)","volume":"34","author":"Geller","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0036","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1001\/archderm.137.1.14","article-title":"Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1\u2013positive man","volume":"137","author":"Pehoushek","year":"2001","journal-title":"Arch Dermatol"},{"issue":"15","key":"10.1016\/j.clindermatol.2025.09.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0b013e32833d466c","article-title":"A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod","volume":"24","author":"Fox","year":"2010","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.clindermatol.2025.09.014_bib0038","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/archderm.142.11.1438","article-title":"Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men","volume":"142","author":"Wieland","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0039","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jaad.2012.06.009","volume":"67","author":"Connolly","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jaad.2020.08.077","article-title":"Low CD4+ T-cell nadir as a preoperative risk factor for squamous cell carcinoma with larger surgical margins during Mohs micrographic surgery among patients infected with HIV","volume":"84","author":"Chow","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.clindermatol.2025.09.014_bib0041","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/DSS.0000000000003457","article-title":"Nonmelanoma skin cancers treated with Mohs micrographic surgery in patients with HIV: a cross-sectional analysis","volume":"48","author":"Lewis","year":"2022","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0042","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamadermatol.2016.0192","article-title":"Nonmelanoma Skin Cancer With Aggressive Subclinical Extension in Immunosuppressed Patients","volume":"152","author":"Song","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0043","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced casal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0044","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4103\/ijdvl.IJDVL_92_18","article-title":"Vismodegib treatment in a HIV positive patient on antiretroviral therapy","volume":"84","author":"Scalvenzi","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/01676830.2020.1753783","article-title":"Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib","volume":"40","author":"Tran","year":"2021","journal-title":"Orbit"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0046","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/17460441.2014.920816","article-title":"Discovery and preclinical development of vismodegib","volume":"9","author":"Gould","year":"2014","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0047","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0048","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","volume":"77","author":"Bhutani","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0049","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0050","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with hiv infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0051","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0053","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0052","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.014_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5228","article-title":"Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: a case report","volume":"9","author":"Alloghbi","year":"2021","journal-title":"Clin Case Rep"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25002299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25002299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:37:14Z","timestamp":1780335434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X25002299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0738081X25002299"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.09.014","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin cancer and human immunodeficiency virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}